Comparison of Two Treatment Regimens (Sitagliptin Versus Liraglutide) on Participants Who Failed to Achieve Good Glucose Control on Metformin Alone (MK-0431-403)
NCT01296412 on ClinicalTrials.gov · last registry update 2017-06-09
Finished 29 February 2012, after enrolling 653 people. Primary outcome, as filed: Change From Baseline in Hemoglobin A1c (A1C). liraglutide is already approved in the US for type 2 diabetes, so this is asking a further question rather than establishing the drug works at all.
- Status
- COMPLETED
- Phase
- P3
- Drug
- liraglutideSaxenda, Victoza, Xultophy
- Sponsor
- Merck Sharp & Dohme LLC
- Sponsor type
- Industry
- Enrollment
- 653
- Started
- 2011-03-11
- Primary completion
- 2012-02-29 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Change From Baseline in Hemoglobin A1c (A1C)
Conditions studied
Diabetes Mellitus, Type 2
Every field above is taken directly from the registry record. See all detected changes across the class, or the liraglutide page for this molecule’s full trial and approval history.